QNTM Soars 30% on $21M ATM Offering and Phase 2 Trial Approval
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Quantum BioPharma Ltd (NASDAQ: QNTM, CSE: QNTM, FRA: 0K91) is a biopharmaceutical company based in Toronto that develops therapies for neurodegenerative and inflammatory disorders. Its lead asset, Lucid-MS, is a patented new chemical entity aimed at preventing and reversing myelin degradation associated with multiple sclerosis. The company also owns rights to unbuzzd™, a beverage designed to support brain and liver function after alcohol consumption.
Corporate Structure and Leadership
Quantum BioPharma employs between 11 and 50 staff, including scientists with backgrounds at the FDA, major pharmaceutical companies, and academic institutions. The leadership team includes:
- Dr. Lakshmi Kotra: Julia Levy Award recipient overseeing pipeline development.
- Kevin Harrington: Investor known for his role on Shark Tank and experience in product launches.
- Gerry David: Former CEO of Celsius Holdings (NASDAQ: CELH), known for substantial market capitalization increase.
- John Duffy Jr.: Former Vice President of National Sales at Coca-Cola, responsible for large-scale distribution.
Through its subsidiary Lucid Psycheceuticals Inc., the company is engaged in advancing clinical programs. FSD Strategic Investments Inc., another wholly-owned subsidiary, manages loans secured by residential or commercial property.
Biopharmaceuticals by little plant
Recent Developments
- May 28, 2025: FSD Pharma Australia Pty Ltd obtained approval from the Human Research Ethics Committee for a Phase 2 trial of FSD202 in participants with nociplastic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS). The trial will enroll 60 patients receiving FSD202 or placebo twice daily over 56 days, focusing on primary endpoints measured at Day 28.
- October 31, 2025: Quantum BioPharma entered an at-the-market offering agreement with H.C. Wainwright & Co., LLC, allowing for the sale of up to US$21.225 million of Class B subordinate voting shares, with a 3.0% commission on gross proceeds.
- November 7, 2025 & November 25, 2025: The company filed two Form 6-K reports with the SEC, each referencing press releases related to corporate updates and operational progress.
Financial and Strategic Analysis
On November 26, 2025, QNTM closed at US$10.50 on Nasdaq, reflecting a 30.60% increase from the previous close of US$8.04. Trading volume reached 818,134 shares. The stock has fluctuated between US$2.70 (December 20, 2024) and US$38.25 (June 20, 2025) over the past year.
| Metric | Value |
|---|---|
| Last Price (11/26/2025) | US$10.50 |
| Price Change (%) | +30.60% |
| Volume | 818,134 |
| 52-Week High | US$38.25 (06/20/2025) |
| 52-Week Low | US$2.70 (12/20/2024) |
| Open (11/26/2025) | US$8.70 |
| Day High | US$11.00 |
| Day Low | US$8.70 |
| Previous Close | US$8.04 |
The company reports no debt and has sufficient working capital to support operations through 2025. The at-the-market offering is intended to provide additional financing for clinical studies, research and development, and general corporate purposes. The licensing agreements include a 7% royalty on unbuzzd™ sales until US$250 million is reached, after which the royalty drops to 3% indefinitely.
Market Position and Industry Context
Quantum BioPharma is addressing a US$23 billion market for multiple sclerosis and a US$238 billion mental health sector. Lucid-MS has completed Phase 1 trials in healthy volunteers and is progressing toward Phase 2 studies. The preclinical efficacy of Lucid-MS in remyelination has been published in peer-reviewed journals. The consumer-facing unbuzzd™ beverage is scheduled for launch in 2024, contributing to diversified revenue.
The company holds exclusive intellectual property rights and benefits from the experience of its leadership in product launches and neuroscience research. Its public listings on Nasdaq and the Canadian Securities Exchange provide access to capital markets for shareholder liquidity.
tl;dr
On November 26, 2025, Quantum BioPharma’s stock reached US$10.50 (+30.60%) following the October 31 announcement of an up-to-US$21.225 million at-the-market offering. Approval obtained on May 28, 2025, enabled a Phase 2 trial of FSD202 for MCAS-associated pain. The company reports no debt, projecting adequate funds through 2025, and unbuzzd™ royalties capped at US$250 million. Lucid-MS has completed Phase 1 dosing; proceeds from the ATM offering will support upcoming clinical and research milestones.